Cargando…

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

The success of cancer immunotherapy with immune checkpoint blockade (ICB) has demonstrated the importance of targeting a preexisting immune response in a broad spectrum of tumors. This is particularly novel and relevant for less immunogenic tumors, such as breast cancer (BC), where the efficacy of I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellegrino, B., Musolino, A., Llop-Guevara, A., Serra, V., De Silva, P., Hlavata, Z., Sangiolo, D., Willard-Gallo, K., Solinas, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2020
Materias:	Review article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948367/ https://www.ncbi.nlm.nih.gov/pubmed/31901781 http://dx.doi.org/10.1016/j.tranon.2019.10.010

Ejemplares similares

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
por: Pellegrino, Benedetta, et al.
Publicado: (2021)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
por: Pellegrino, Benedetta, et al.
Publicado: (2019)

Leveraging homologous recombination repair deficiency in sarcoma
por: Slade, Dea, et al.
Publicado: (2023)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
por: Capoluongo, E.D., et al.
Publicado: (2022)

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report
por: Gomez-Puerto, Diego, et al.
Publicado: (2022)

Homologous recombination-deficient tumors are hyper-dependent on POLQ-mediated repair
por: Ceccaldi, Raphael, et al.
Publicado: (2015)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer
por: Wang, Yue, et al.
Publicado: (2017)

The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes
por: Štancl, Paula, et al.
Publicado: (2022)

Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
por: Planas‐Paz, Lara, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Homologous Recombination Deficiencies and Hereditary Tumors
por: Yamamoto, Hideki, et al.
Publicado: (2021)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
por: Pacheco-Barcia, Vilma, et al.
Publicado: (2022)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Targeting homologous recombination deficiency in uterine leiomyosarcoma
por: Dall, Genevieve, et al.
Publicado: (2023)

Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma
por: Goričar, Katja, et al.
Publicado: (2015)

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer
por: Solinas, Cinzia, et al.
Publicado: (2019)

Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects
por: Sulkowski, Parker L., et al.
Publicado: (2018)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review
por: Tan, Heng, et al.
Publicado: (2023)

Pan-cancer landscape of homologous recombination deficiency
por: Nguyen, Luan, et al.
Publicado: (2020)

Homologous Recombination Deficiency: Concepts, Definitions, and Assays
por: Stewart, Mark D, et al.
Publicado: (2022)

DEK is required for homologous recombination repair of DNA breaks
por: Smith, Eric A., et al.
Publicado: (2017)

Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma
por: Liu, Hangqi, et al.
Publicado: (2022)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer
por: Khaddour, Karam, et al.
Publicado: (2022)

Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors
por: Farmanbar, Amir, et al.
Publicado: (2023)

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
por: Shi, Zhiwen, et al.
Publicado: (2021)

Analysis of repair mechanism choice during homologous recombination
por: Agmon, Neta, et al.
Publicado: (2009)

Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer
por: Jönsson, Jenny-Maria, et al.
Publicado: (2021)

A plant-specific module for homologous recombination repair
por: Wang, Xuanpeng, et al.
Publicado: (2022)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
por: Tsantikidi, Aikaterini, et al.
Publicado: (2023)

Regulators of homologous recombination repair as novel targets for cancer treatment
por: Krajewska, Małgorzata, et al.
Publicado: (2015)

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
por: Porcu, Michele, et al.
Publicado: (2019)

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature
por: Frey, Melissa K., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bce8g446jjev7dkdnc9dq18rkp